Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.170 -0.010 (-0.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,436,173
Open 1.170
Bid (Size) 1.170 (700)
Ask (Size) 1.190 (1,000)
Prev. Close 1.180
Today's Range 1.115 - 1.200
52wk Range 0.2836 - 1.660
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+50.6%
+50.6%
1 Month
-20.4%
-20.4%
3 Month
-4.1%
-4.1%
6 Month
+56.0%
+56.0%
1 Year
+72.8%
+72.8%

More News

Read More
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
Topics Stocks
News headline image
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q2 Revenue Soars 1,706% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5% ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.170
When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 12/19/25 04:00 PM ET
What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 169.04M
How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
Lexicon Pharmaceuticals, Inc. - Common Stock has 169M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.